Genmab A/S (GMAB) Reports Q2 Net Sales of DARZALEX of $1.97B

Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) formulation (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 1,986 million in the second quarter of 2022. Net trade sales were USD 1,021 million in the U.S. and USD 965 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC formulations, under the exclusive worldwide license to Janssen to develop, manufacture and commercialize daratumumab.

You May Also Be Interested In

• Genmab Announces Financial Results for the First Half of 2026
• AMTD IDEA receives NYSE non-compliance notice over ADS price
• KKR closes equity investment in Crowe Advisory LLC